VALSARTAN AND HYDROCHLOROTHIAZIDE tablet, film coated

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

VALSARTAN (UNII: 80M03YXJ7I) (VALSARTAN - UNII:80M03YXJ7I), HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)

Inapatikana kutoka:

Aurobindo Pharma Limited

INN (Jina la Kimataifa):

VALSARTAN

Tungo:

VALSARTAN 80 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

Valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the angiotensin II receptor blocker (ARB) class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National Hi

Bidhaa muhtasari:

Valsartan and hydrochlorothiazide tablets, USP are available as non-scored tablets containing valsartan and hydrochlorothiazide 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg. Strengths are available as follows. Valsartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg are light orange colored, ovaloid, beveled edge, biconvex film-coated tablets debossed with 'I' on one side and '61' on other side.          Bottles of 90                                                        NDC 65862-547-90          Bottles of 1,000                                                   NDC 65862-547-99          Cartons of 100 (10 x 10) Unit-dose Tablets         NDC 65862-547-10 Valsartan and Hydrochlorothiazide Tablets USP, 160 mg/12.5 mg are dark red colored, ovaloid, beveled edge, biconvex film-coated tablets debossed with 'I' on one side and '62' on other side.          Bottles of 90                                                        NDC 65862-548-90          Bottles of 1,000                                                    NDC 65862-548-99          Cartons of 100 (10 x 10) Unit-dose Tablets         NDC 65862-548-10 Valsartan and Hydrochlorothiazide Tablets USP, 160 mg/25 mg are brown-orange colored, ovaloid, beveled edge, biconvex film-coated tablets debossed with 'I' on one side and '63' on other side.          Bottles of 90                                                        NDC 65862-549-90          Bottles of 1,000                                                   NDC 65862-549-99          Cartons of 100 (10 x 10) Unit-dose Tablets         NDC 65862-549-10 Valsartan and Hydrochlorothiazide Tablets USP, 320 mg/12.5 mg are pink colored, oval shaped, beveled edge, biconvex film-coated tablets debossed with 'I' on one side and '64' on other side.          Bottles of 90                                                        NDC 65862-550-90          Bottles of 500                                                      NDC 65862-550-05 Valsartan and Hydrochlorothiazide Tablets USP, 320 mg/25 mg are yellow colored, oval shaped, beveled edge, biconvex film-coated tablets debossed with 'I' on one side and '65' on other side.          Bottles of 90                                                        NDC 65862-551-90          Bottles of 500                                                      NDC 65862-551-05 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from moisture and heat. Dispense in tight container (USP).

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

VALSARTAN AND HYDROCHLOROTHIAZIDE - VALSARTAN AND HYDROCHLOROTHIAZIDE
TABLET,
FILM COATED
AUROBINDO PHARMA LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
VALSARTAN
AND HYDROCHLOROTHIAZIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION
FOR VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS.
VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING. _
WHEN PREGNANCY IS DETECTED, DISCONTINUE VALSARTAN AND
HYDROCHLOROTHIAZIDE AS SOON AS POSSIBLE. (5.1)
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH TO THE DEVELOPING
FETUS. (5.1)
INDICATIONS AND USAGE
Valsartan and hydrochlorothiazide is the combination tablet of
valsartan, an angiotensin II receptor blocker (ARB) and
hydrochlorothiazide, a diuretic.
Valsartan and hydrochlorothiazide tablets are indicated for the
treatment of hypertension, to lower blood pressure:
In patients not adequately controlled with monotherapy (1)
As initial therapy in patients likely to need multiple drugs to
achieve their blood pressure goals (1)
Lowering blood pressure reduces the risk of fatal and nonfatal
cardiovascular events, primarily strokes and myocardial
infarctions .
DOSAGE AND ADMINISTRATION
Dose once daily. Titrate as needed to a maximum dose of 320 mg/25 mg
(2)
May be used as add-on/switch therapy for patients not adequately
controlled on any of the components (valsartan or
hydrochlorothiazide) (2)
May be substituted for titrated components (2.3)
DOSAGE FORMS AND STRENGTHS
Tablets (valsartan and hydrochlorothiazide): 80 mg/12.5 mg, 160
mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320
mg/25 mg. (3)
CONTRAINDICATIONS
Anuria; Hypersensitivity to any sulfonamide-derived drugs or any
component; Do not coadminister aliskiren with valsartan
and hydrochlorothiazide tablets in patients with diabetes (4)
WARNINGS AND PRECAUTIONS
Hypotension: Correct volume dep